[1] LOCATELLI F,PISONI R L,COMBE C,et al.Anaemia in haemodialysis patients of five European countries:association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)[J].Nephrol Dial Transplant,2004,19(1):121-132.
[2] STEINBERG D.Atherogenesis in perspective:hypercholesterolemia and inflammation as partners in crime[J].Nat Med,2002,8(11):1211-1217.
[3] KRAFT H G,KÖCHL S,MENZEL H J,et al.The apolipoprotein (a) gene:a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration[J].Hum Genet,1992,90(3):220-230.
[4] KOSTNER K M,CLODI M,BODLAJ G,et al.Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function[J].Eur J Clin Invest,1998,28(1):447-452.
[5] BROWN M S,GOLDSTEIN J L.A receptor-mediated pathway for cholesterol homeostasis[J].Science,1986,232:34-47.
[6] 吕汉叶.急性冠状动脉综合征患者血清sol-CXCL16的表达规律[J].东南大学学报(医学版),2016,35(5):709-713.
[7] WILBANKS A L,ZONDLO S C,MURPHY K,et al.Expression cloning of the STRL33/BONZO/TYMSTR ligand reveals elements of CC,CXC,and CX3C chemokines[J].J Immunol,2001,166(8):5145-5154.
[8] UTERMANN G,WEBER W.Protein composition of Lp(a) lipoprotein from human plasma[J].FEBS Lett,1983,154:357-361.
[9] FOLEY R N,PARFREY P S,SARNAK M J.Clinical epidemiology of cardiovascular disease in chronic renal disease[J].Am J Kidney Dis,1998,32:S112-S119.
[10] MARCOVINA S M,KOSCHINSKY M L,ALBERS J J,et al.Report of the National Heart,Lung,and Blood Institute Workshop on lipoprotein (a) and cardiovascular disease:recent advances and future directions[J].Clin Chem,2003,49:1785-1796.
[11] BENNET A E,di ANGELANTONIO S,ERQOU G,et al.Lipoprotein(a) levels and risk of future coronary heart disease:large-scale prospective data[J].Arch Intern Med,2008,168:598-608.
[12] KAMSTRUP P R,TYBJAERG-HANSEN A,STEFFENSEN R,et al.Genetically elevated lipoprotein(a) and increased risk of myocardial infarction[J].JAMA,2009,301:2331-2339.
[13] MICHAEL B,BOFFA M L,KOSCHINSKY.Update on lipoprotein(a) as a cardiovascular risk factor and meditator[J].Curr Atheroscler Rep,2013,15(10):360.
[14] TANJA X,PEDERSEN S P,MCCORMIC K,et al.Lipoprotein(a) accelerates atherosclerosis in uremic mice[J].J Lipid Res,2010,51:2967-2975.
[15] BOFFA M B,KOSCHINSKY M L.Update on lipoprotein(a) as a cardiovascular risk factor and mediator[J].Curr Atheroscler Rep,2013,15(10):360.
[16] UTERMANN G,WEBER W.Protein composition of Lp(a) lipoprotein from human plasma[J].FEBS Lett,1983,154(2):357-361.
[17] MA K L,RUON X Z,POWIS S H,et al.Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells[J].Am J Phvsiol Heart Cire Physiol,2007,292:2721-2728.
[18] RUAN X Z,MOORHEAD J F,TAO J L,et al.Mechanisms of dysregulation of low-density lipoprotein receptor expression in vascular smooth muscle cells by inflammatory cytokines[J].Arterioscler Thromb Vasc Biol,2006,26(5):1150-1155.
[19] WUTTGE D M,ZHOU X,SHEIKINE Y,et al.CXCLl6/SR-PSOX is an interferon- gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions[J].Arterioscler Thromb Vase Biol,2004,24(4):750-755.
[20] YANG X P,AMAR M J,VAISMAN B,et al.Scavenger receptor-BI is a receptor for lipoprotein (a)[J].J Lipid Res,2013,54:2450-2457.
[21] HOFMANN S L,EATON D L,BROWN M S,et al.Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp (a) lipoprotein in transgenic mice[J].J Clin Invest,1990,85:1542-1547.
[22] NIEMEIER A,WILLNOW T,DIEPLINGER H,et al.Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro[J].Arterioscler Thromb Vasc Biol,1999,19:552-561. |